# Detecting EGFR Gene Mutations on a Nanobioarray Chip

## TL;DR

This study presents a nanobioarray chip method to detect EGFR gene mutations in lung cancer patients, helping determine drug sensitivity or resistance.

## Contribution

A gold nanoparticle-assisted method on a 16-channel nanobioarray chip for rapid EGFR mutation detection is introduced.

## Key findings

- The method successfully differentiates wild-type and mutated EGFR sequences.
- Gold nanoparticle-assisted wash improves detection accuracy for TKI-sensitive and resistant mutations.
- The technique targets three clinically relevant EGFR point mutations in lung cancer.

## Abstract

In this study, three point mutations of EGFR relevant to lung cancer therapy are detected. Mutated EGFR is the target of a therapy for non-small cell lung cancer (NSCLC) using tyrosine kinase inhibitors (TKIs) as treatment drugs. Background/Objectives: Point mutations in exon 21 (L858R and L861Q) of the EGFR gene are TKI-sensitive; however, mutations in exon 20 (T790M) are TKI-resistant. Therefore, a fast detection method that classifies an NSCLC patient to be drug sensitive or drug resistant is highly clinically relevant. Methods: Probes were designed to detect three point mutations in genomic samples based on DNA hybridization on a solid surface. A method has been developed to detect single nucleotide polymorphism (SNP) for these mutation detections in the 16-channel nanobioarray chip. The wash by gold-nanoparticles (AuNP) was used to assist the differentiation detection. Results: The gold nanoparticle-assisted wash method has enhanced differentiation between WT and mutated sequences relevant to the EGFR sensitivity to tyrosine kinase inhibitors. Conclusions: The WT and mutated sequences (T790M, L858R and L861Q) in genomic samples were successfully differentiated from each other.